ProCE Banner Activity

Pooled Analysis of Trastuzumab Deruxtecan Efficacy and Safety by Age in Patients With HER2+ Metastatic Breast Cancer From DESTINY-Breast01, 02, and 03 Trials

Conference Coverage
Slideset

A pooled analysis of data from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 indicates that T-DXd is a safe and effective treatment option for patients with MBC ≥65 years old.

Released: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.